Summary of Ultragenyx Q1 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $136 million for Q1 2026.

Crysvita: $93 million (North America: $39 million, Latin America and Turkey: $46 million, Europe: $8 million).

Dojolvi: $18 million, consistent with steady growth.

Evkeeza: $18 million, representing a 64% increase year-over-year.

Mepsevii: $7 million.

Operating Expenses: $305 million, including $30 million in cost of sales and $275 million in combined R&D and SG&A expenses.

Net Loss: $185 million, or $1.84 per share.

Cash Position: $534 million in cash, cash equivalents, and marketable securities.

Net Cash Used in Operations: $197 million, expected to decrease in subsequent quarters.

2Strategic Updates and Business Highlights

Transformative Year: 2026 is expected to be transformative with anticipated revenue exceeding $700 million and multiple new drug approvals.

Gene Therapy Developments: PDUFA dates set for GTX-102 (Angelman syndrome), DTX401, and UX111, with the latter two expected to launch in late 2026.

Clinical Trials: Continued enrollment in the Phase 3 Aspire study for GTX-102, with promising long-term data showing benefits for patients.

Global Commercialization: Revenue generation in over 35 countries, with a focus on building a robust commercial infrastructure to support new product launches.

3Forward Guidance and Outlook

2026 Revenue Guidance: Reaffirmed guidance of $730 million to $760 million, reflecting 8% to 13% growth over 2025.

Crysvita Revenue Expectation: Projected between $500 million and $520 million.

Dojolvi Revenue Expectation: Projected between $100 million and $110 million.

R&D and SG&A Expenses: Expected to remain flat or decrease slightly compared to 2025.

4Bad News, Challenges, or Points of Concern

High Operating Expenses: Total operating expenses remain significant, leading to a substantial net loss.

Discontinuation Rates: While currently low, there are concerns about potential patient discontinuations due to the burden of study participation in clinical trials.

Regulatory Risks: The success of upcoming product launches and the ability to navigate complex reimbursement processes pose ongoing risks.

Market Competition: The company is focused on rare diseases with limited competition, but the landscape remains challenging with the influx of late-stage programs.

5Notable Q&A Insights

MDRI vs. Bayley-4 Cognition: The company expressed more confidence in the MDRI as a robust measure for assessing treatment efficacy in Angelman syndrome, while acknowledging the Bayley-4 as a critical endpoint.

Sham Performance in Trials: Management is confident that sham performance will not significantly affect outcomes in the Aspire study, based on historical data.

Discontinuation Management: Plans are in place to minimize discontinuation rates in the commercial setting, focusing on patient convenience and support.

PRV Monetization: The company plans to monetize two Priority Review Vouchers (PRVs) from upcoming launches, which could provide additional financial upside. Overall, Ultragenyx is positioned for growth with a strong pipeline and strategic focus on rare diseases, despite facing challenges related to high operating costs and regulatory complexities.